|
|
Volumn 33, Issue 3, 2002, Pages 232-233
|
|
To the editor: Is it safe to administer a continuous infusion of ceftazidime (Fortum®) prepared for 24 hours in cystic fibrosis (CF) patients? [1]
a a a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALANINE AMINOTRANSFERASE;
AMOXICILLIN PLUS CLAVULANIC ACID;
ASPARTATE AMINOTRANSFERASE;
CEFEPIME;
CEFTAZIDIME;
CILASTATIN PLUS IMIPENEM;
FOSFOCINE;
FOSFOMYCIN;
FUSIDATE SODIUM;
OXACILLIN;
PIPERACILLIN;
PIPERACILLIN PLUS TAZOBACTAM;
RIFAMPICIN;
TICARCILLIN;
TIMENTIN;
TOBRAMYCIN;
VANCOMYCIN;
VANCOMYCINE;
ALANINE AMINOTRANSFERASE BLOOD LEVEL;
ANTIBIOTIC THERAPY;
ASPARTATE AMINOTRANSFERASE BLOOD LEVEL;
CYSTIC FIBROSIS;
DRUG EFFICACY;
DRUG SAFETY;
DRUG STABILITY;
GRAM NEGATIVE INFECTION;
HUMAN;
LETTER;
LIVER TOXICITY;
MAJOR CLINICAL STUDY;
PRIORITY JOURNAL;
PSEUDOMONAS AERUGINOSA;
CEFTAZIDIME;
CYSTIC FIBROSIS;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
INFUSIONS, INTRAVENOUS;
KIDNEY;
LIVER;
PSEUDOMONAS INFECTIONS;
RETROSPECTIVE STUDIES;
TREATMENT OUTCOME;
|
|
EID: 0036179663
PISSN: 87556863
EISSN: None
Source Type: Journal
DOI: 10.1002/ppul.10051 Document Type: Letter |
|
Times cited : (7)
|
|
References (4)
|
